FDA Approves Opus Genetics’ RYZUMVI for Adult Presbyopia

The primary source explicitly reports that the FDA approved Opus Genetics’ supplemental New Drug Application for phentolamine ophthalmic solution 0.75% for adult presbyopia on October 16, 2026. This is a new, entity-specific regulatory authorization with forward-looking commercialization and licensing implications, including a milestone payment to Opus Genetics and exclusive U.S. commercialization rights for Viatris; therefore, regulatory_approval is the appropriate type and the development is approved for output. Importance is high but narrower than a broad market or sector catalyst because the direct effects are concentrated on Opus Genetics, Viatris, and competing presbyopia therapies. Surprise is moderated because the application had been accepted for review, a PDUFA date was known, and the pivotal Phase 3 results were positive, making approval partly anticipated rather than an unexpected shock. Confidence is very high because the approval, product, indication, supporting trials, and licensing implications are explicitly described. The source establishes the calendar date but not the exact FDA decision time, so the timestamp is normalized to the start of October 16 in UTC with reduced timestamp confidence. The prior event match is retained: this approval is a distinct milestone that advances the existing Opus Genetics phentolamine clinical-development storyline. Approved stakeholders are limited to Opus Genetics and Viatris as direct beneficiaries, plus LENZ and AbbVie as companies with explicitly identified competing prescription presbyopia products; Eyenovia and Novartis are excluded because their cited programs are earlier-stage and the effect is more speculative.